Trading Members of the Exchange are hereby informed that effective from Thursday March 16, 2017, the equity shares of Parmax Pharma Limited are listed and admitted to dealings on the Exchange in the list of XT Group.
|
Name of the company
|
Securities
|
Market Lot
|
Scrip Code
|
|
Parmax Pharma Limited
|
37,41,300 Equity
shares of Rs. 10 /-
(Face value) each
fully paid-up.
Distinctive numbers:
1 to 5100800*
|
One Share
|
540359
|
|
Registered Office Address:
|
Abbreviated Name on BOLT Plus System
|
Scrip ID on BOLT Plus System
|
ISIN No.
|
|
Plot No. 20, Survey No. 52, 8B – Rajkot – Gondal National Highway, Hadamtala, Tal. Kotda Sangani, Rajkot – 360311
Phone: 02827 – 270534/535
Website: www.parmaxpharma.com
Email ID for Investor Grievances:
parmaxpharma@gmail.com
|
PARMAX
|
PARMAX
|
INE240T01014
|
*Includes 342490 & 748260 equity shares held by promoters which are to be kept under lock - in till March 02, 2018 and March 02, 2020 and 1359500 forfeited shares respectively.
1. Trading Members may note that as per the guidelines issued by SEBI dated 16th February, 2000, securities of the company will only be traded in Dematerialised form. Trades effected in this scrip will be in unit market lot (i.e. one share).
2. The trading in the scrip shall continue to remain in Trade-for-Trade segment till further notice since 100% of Promoter shareholding & 50% Public shareholding of the company is not in demat form, as per extent SEBI guidelines.
3. The Trading Members may please note that the above mentioned scrip will be a part of Special Pre-open Session (SPOS) for IPO’s & Relisted Scrips - Relist session on Thursday March 16, 2017
For further information on SPOS, the Trading Members are requested to refer to the Exchange’s notice no. 20120216-29 on Enabling Special Pre-open Session for IPO’s & Relisted Scrips.
For any clarification on the above, the Trading Members may please contact the Helpdesk on 022-6136 3100 / 6136 3171.
4. The Equity shares of the Company are listed on Ahmedabad Stock Exchange Limited
5. The unaudited financial result of the Company for the Quarter-ended December 31, 2016 is enclosed as Annexure I.
6. A copy of the Shareholding Pattern as on December 31, 2016 as submitted by the company, is enclosed as Annexure II.
7. The Company’s financial year ending is March 31.
8. The Company Profile containing all the information about the company can be viewed at www.bseindia.com/corporates/direct_list.aspx?expandable=1
9. The address of the Registrar and Transfer Agent of the Company is given below:
Purva Sharegistry (India) Private Limited
Unit No. 9, Shiv Shakti Ind Industrial Estate,
J.R.Boricha Marg, Opp. Kasturba Hospital Lane,
Lower Parel (East),
Mumbai – 400011.
.
In case Trading Members require any clarifications on the subject matter of this Notice, they may please contact any of the following:
|
A) At the company:
Tausif U. Chandiwala
(Company Secretary &
Compliance Officer)
Mobile No. 9904897775
|
Plot No. 20, Survey No. 52, 8B – Rajkot – Gondal National Highway, Hadamtala, Tal. Kotda Sangani, Rajkot – 360311
Phone: 02827 – 270534/535
Website: www.parmaxpharma.com
Email ID for Investor Grievances:
parmaxpharma@gmail.com
|
|
B) At the Exchange:
Mr. Atul Dhotre
Manager – Listing
|
Tel.No.: +91-22-22728934
|
Khyati Shah Atul Dhotre
Dy. Gen. Manager Manager
Tuesday March 14, 2017
Encl: a/a |